TG Therapeutics | TGTX - Operating Expenses

Stock Price
29.66
Daily Change
-0.85 -2.79%
Monthly
-3.32%
Yearly
1.09%
Q1 Forecast
28.61

TG Therapeutics reported $132.34M in Operating Expenses for its fiscal quarter ending in September of 2025.





Operating Expenses Change Date
AbbVie USD 10.81B 13.45B Dec/2025
Alaunos Therapeutics USD 1.19M 428K Sep/2025
Amgen USD 5.9B 773M Dec/2025
Ardelyx USD 105.66M 6.4M Sep/2025
Arrowhead Research USD 223.22M 10.86M Dec/2025
Bayer EUR 10.2B 523M Sep/2025
Biogen USD 1.88B 81.4M Sep/2025
Corcept Therapeutics USD 197.64M 219K Dec/2025
Curis USD -13.99M 7.38M Jun/2025
Gilead Sciences USD 4.96B 707M Dec/2025
Infinity Pharmaceuticals USD 10.7M 1.54M Jun/2023
J&J USD 18.97B 2.38B Dec/2025
Karyopharm Therapeutics USD 61.82M 3.24M Dec/2024
Novartis USD 9.86B 115M Sep/2025
Novavax USD 218.53M 34.86M Sep/2024
PTC Therapeutics USD 246.3M 38.78M Dec/2025
Puma Biotechnology USD 49.26M 3.2M Jun/2024
Regeneron Pharmaceuticals USD 2.99B 27.97B Dec/2025
Roche Holding CHF 21.01B 10.84B Dec/2025
TG Therapeutics USD 132.34M 26.04M Sep/2025
Verastem USD 37.03M 8.97M Sep/2024
Vertex Pharmaceuticals USD 1.93B 89.1M Dec/2025